Sep 2026· Recent Advances in Drug Delivery and Formulation· 0 citations
Medicine
TL;DR
Although considerable advancements have been made in treating biofilm infections through the use of nanocarriers, there are still several issues that need to be addressed before moving into clinical practice.
Abstract
Biofilms are structured communities of microorganisms encapsulated by an Extracellular Polymeric Substance (EPS) matrix, which plays a crucial role in recurrent and chronic infections caused by implanted medical devices. The natural resistance of biofilms to antimicrobials and the difficulty in diagnosing them pose a challenge in the fight against infections. The biofilm life cycle, consisting of attachment, maturation, and dispersion stages, further complicates this issue. Nanocarriers have increasingly been proposed to overcome the challenges posed by biofilms because of their small size, large surface area-to-volume ratio, and physicochemical properties. Due to the unique characteristics of nanocarriers, researchers have used them to facilitate antimicrobial delivery, enhance drug permeability into biofilms, and promote the effects of the administered drugs. Researchers have used various techniques such as quorum-sensing inhibition, EPS matrix breakdown, and targeted drug delivery to treat biofilm infections. Although considerable advancements have been made in treating biofilm infections through the use of nanocarriers, there are still several issues that need to be addressed before moving into clinical practice.
Comparative studies suggest that combination approaches, including enzyme functionalized or stimuli responsive nanoparticles paired with antibiotics, may outperform single modality treatments by simultaneously disrupting the biofilm matrix and delivering active agents.
Husni Farah, Munthar Kadhim-Abosaoda, Hayjaa Mohaisen-Mousa et al.· Microfluidics and Nanofluidi...· 0 citations
This review establishes a consolidated evidence base for the design of next-generation antimicrobial nanoformulations, highlights their potential to address biofilm-associated infections, and identifies key knowledge gaps and translation barriers that must be addressed to realize their therapeutic promise.
Praveen Kumar Annagowni, Renuka Gudepu, S. Dahariya et al.· Micro· 0 citations
Bacterial biofilms pose significant challenges in clinical and industrial settings because of their resistance up to 1000-fold higher than that of planktonic bacteria. This resistance arises from extracellular polymeric matrix, reduced metabolic activity, and horizontal gene transfer. The growing burden of biofilm-asso...
I. C. Oladipo, K. Oloyede, O. B. Ogunleke et al.· Nano Plus Science and Techno...· 0 citations
This narrative review synthesizes current evidence on nanozyme applications for overcoming biofilm-associated challenges in periodontitis, focusing on antibiofilm mechanisms, representative platforms, delivery strategies, and translational hurdles.
Yu-Jie Ji, Tian-Yu Huang, Qiu-Dong Xu et al.· Frontiers in Bioengineering...· 0 citations
The problem of biofilm infections is of considerable clinical
importance because of the presence of an EPS matrix, metabolic heterogeneity, and antimicrobial
tolerance, leading to low penetration of antibiotics and contributing to the failure of therapy and the
development of antimicrobial resistance. This review a...
Aruna Sharma, Ameya Sharma, Divya Dheer et al.· Recent Patents on Nanotechno...· 0 citations
This review provides an integrated overview of the molecular and genetic determinants governing biofilm development, including surface attachment, matrix biosynthesis, quorum-sensing networks, cyclic-di-GMP signaling, maturation, and dispersal.
T. Chakraborty, Madhuchhanda Chatterjee, Sayanika Das et al.· Infection, Genetics and Evol...· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.